1969

 

This Washington Post advertisement appeared a few months after the first landing on the moon (1969). It quoted Dr. Sidney Farber, oncologist and past president of the American Cancer Society: “We are so close to a cure for cancer. We lack only the will and the kind of money and comprehensive planning that went into putting a man on the moon.” {ref}

No Overall Survival Difference With PARP Inhibitor Maintenance Therapy in Ovarian Cancer

Data from the ENGOT-OV16/NOVA study show NO difference in overall survival (OS) for patients with platinum-sensitive recurrent ovarian cancer who received poly (ADP-ribose) polymerase (PARP) inhibitor Niraparib maintenance therapy and those who did not. 

https://www.pharmacytimes.com/view/long-term-follow-up-shows-no-overall-survival-difference-with-parp-inhibitor-maintenance-therapy-in-ovarian-cancer

OS hazard ratio numerically favored Niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort (approximately 85% of epithelial ovarian cancer patients are in this group!).

Gel Stops Mouse Brain Tumors, Offers Hope for Humans

A gel completely cured mice with deadly brain cancer, a startling finding that gives patients with glioblastoma - one of the deadliest and most prevalent brain tumors in humans - new hope 

This hydrogel delivers intracranial immunotherapy together with chemotherapy.

https://hub.jhu.edu/2023/04/24/mouse-brain-tumors-glioblastoma/

High Intensity Exercise May Reduce the Risk of Metastatic Cancer by 72%, Study Suggests

Using data from a prospective study, researchers found that participants who regularly engaged in high-intensity aerobic activity had a 72% lower risk of metastatic cancer.

The researchers defined high-intensity exercise as an exercise where your heart rate is 80-85% of your maximum pulse rate, e.g., 132 beats per minute for a 55-year-old. (How to Determine Your Maximum Heart Rate).

The finding from this Tel Aviv University study stems from both epidemiological data in humans and mechanistic investigations in animals, suggesting a metabolic basis for the protective effect of high-intensity aerobic exercise against metastatic cancer.

In the human component, researchers analyzed 20-year follow-up data from nearly 3,000 initially cancer-free participants. Those who regularly performed high-intensity aerobic activities (efforts reaching 80-85% of maximum heart rate, such as vigorous running) showed a 72% lower incidence of metastatic cancer compared to sedentary individuals. This was linked to metabolic shifts observed in a smaller group of runners, where blood samples post-exercise revealed increased carbohydrate metabolism.

The proposed biological mechanism centers on how such exercise alters energy dynamics in the body, making it harder for cancer cells to establish metastases. During high-intensity aerobic activity, muscles and internal organs (like the lungs, liver, and lymph nodes) ramp up their glucose uptake and mitochondrial activity to meet elevated energy demands. This effectively "reprograms" these organs into highly efficient metabolic states, causing them to consume more nutrients and outcompete potential metastatic tumor cells for available glucose, a key energy source that cancer cells rely on for proliferation and spread. In essence, the exercise creates a nutrient-scarce environment in these organs, starving nascent metastases and reducing their ability to grow.

Supporting this, the animal model using mice demonstrated similar effects: those trained with progressive high-intensity treadmill sessions before melanoma cell injection had significantly fewer metastases in distant organs. Proteomic and metabolic analyses revealed enhanced glucose transporters (GLUT proteins) and catabolic processes in the organs of exercised mice, confirming the nutrient competition hypothesis. While the study focused on melanoma in mice, the human data encompassed various cancers, indicating broader applicability; however, it noted a more modest impact on primary (non-metastatic) tumors.

Source: https://www.news-medical.net/news/20221114/High-intensity-aerobic-exercise-can-cut-metastatic-cancer-risk-by-7225.aspx

Half of Belgian patients who received expensive cancer treatments such as Keytruda and Opdivo died within a year of starting this treatment

An analysis of data from approximately 9,000 Belgian patients by the Agence Intermutualiste offers a new reading on the intended target. It seems that half of the patients who received Opdivo treatment (nivolumab) between 2016 and 2018 died during the year. In 2019, that percentage jumped to nearly 70%. Opdivo is a prescription immunotherapy drug used to treat various types of cancer. It’s the brand name for nivolumab, a monoclonal antibody that targets the PD-1 receptor on immune cells.

Similar results are observed for Keytruda, brand name for pembrolizumab, a monoclonal antibody that targets the PD-1 receptor on immune cells, just like Opdivo.

The agency also points out that almost one in ten patients died in the month following the administration of the drug, suggesting that in several cases, the treatment was started when it was no longer appropriate.

Source: https://www.7sur7.be/sante/la-moitie-des-patients-belges-traites-avec-un-nouveau-medicament-contre-le-cancer-sont-morts-dans-lannee~aa8d92d7/

> Promising Compounds to Enhance Nivolumab/Immunotherapy